Home > News > Interim Report Obducat
April 29th, 2004
Interim Report Obducat
Abstract:
Directed new share issue in January 2004 contributed some SEK 13 million, Turnover SEK 4,4 (9,0) million - forecast sales growth of 25-30 per cent in 2004 remains, Obducat partner in EU sponsored nano project NaPa, Pre-tax profit was SEK –9,5 million (–7,9) and earnings per share before deferred dilution was SEK –0,05 (-0,05). (PDF)
Source:
Obducat
Related News Press |
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||